TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Most stories of chikungunya begin with something oddly harmless — a slight twitch in the toes or fingers. That’s when the ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse events included the death of adults aged 62 and 89 years. However, the exact ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...